AstraZeneca PLC to Further Develop Targacept, Inc.'s ADHD Drug; Targacept Eligible to Get Over $100 Million

Reuters -- Targacept Inc said its licensing partner AstraZeneca agreed to pay $10 million milestone payment to further develop Targacept's experimental treatment for attention deficit/hyperactivity disorder (ADHD).